An Opinionated Take on NEJM Highlights for Q1 of 2026

Key Takeaways

• Fish oil halves MI, cuts stroke two‑thirds in dialysis
• Merck's oral PCSK9 inhibitor drops LDL 57%, FDA filing imminent
• Rezatapopt yields 22% response in TP53 Y220C tumors
• AOC delivers siRNA to muscle, reduces DMPK mRNA
• Regeneron gene therapy restores hearing in most treated children

Summary

The first quarter of 2026 NEJM featured several disruptive studies, including a Canadian‑Australian dialysis trial where fish‑oil supplementation halved myocardial infarctions and cut strokes by two‑thirds. Merck’s oral PCSK9 inhibitor enlicitide achieved a 57% LDL reduction, positioning it for a 2026‑27 FDA filing with a national priority voucher. PMV’s rezatapopt reactivated mutant TP53, delivering a 22% response rate in heavily pre‑treated solid tumors, while Avidity’s antibody‑oligo conjugate successfully delivered siRNA to muscle in myotonic dystrophy patients. Regeneron’s split‑AAV gene therapy restored hearing in most children with otoferlin‑related deafness, highlighting a new frontier for genetic medicine.

Pulse Analysis

The cardiovascular landscape is being re‑examined after a surprisingly robust fish‑oil trial in dialysis patients demonstrated dramatic event reductions, prompting clinicians to question whether dietary supplements could complement lipid‑lowering strategies. Simultaneously, Merck’s oral PCSK9 inhibitor enlicitide, which matches injectable agents in LDL‑lowering potency, is poised for regulatory approval under a priority voucher that mandates a 70% discount for direct‑to‑patient purchases. This pricing model could pressure incumbent injectable manufacturers to rethink pricing and distribution, potentially accelerating a shift toward more convenient, oral lipid therapies.

On the oncology front, rezatapopt’s ability to reactivate the Y220C TP53 mutation marks a rare instance of a small‑molecule restoring tumor‑suppressor function, achieving a 22% overall response and an even higher rate in ovarian cancer. The result underscores the growing viability of mutation‑specific drugs and suggests combination regimens with DNA‑damaging agents could amplify efficacy. In parallel, Avidity’s antibody‑oligo conjugate (AOC) demonstrates that targeted siRNA delivery to skeletal muscle is feasible, opening avenues for treating other repeat‑expansion disorders. The technology’s modular nature may catalyze a wave of muscle‑focused RNA therapeutics, expanding the pipeline beyond traditional small molecules.

Regeneron’s split‑AAV gene therapy for otoferlin‑related deafness illustrates how innovative vector engineering can overcome payload size limits, delivering functional hearing restoration even in adolescents. This success broadens the market for inner‑ear gene therapies and hints at a sizable backlog of eligible patients, which could translate into significant revenue streams. Meanwhile, the rise of medical credit cards—high‑interest financing tools for procedures—highlights financing challenges that could affect patient access to these emerging treatments. As insurers and policymakers grapple with cost containment, the intersection of novel therapeutics and patient financing will become a critical determinant of commercial success.